- Home
- FORA vs UNCY Comparison
FORA vs UNCY Comparison
Compare FORA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- UNCY
- Stock Information
- Founded
- FORA 2014
- UNCY 2016
- Country
- FORA United States
- UNCY United States
- Employees
- FORA N/A
- UNCY N/A
- Industry
- FORA Computer Software: Prepackaged Software
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- UNCY Health Care
- Exchange
- FORA Nasdaq
- UNCY Nasdaq
- Market Cap
- FORA 62.7M
- UNCY 58.7M
- IPO Year
- FORA N/A
- UNCY 2021
- Fundamental
- Price
- FORA $2.04
- UNCY $0.57
- Analyst Decision
- FORA Strong Buy
- UNCY Strong Buy
- Analyst Count
- FORA 1
- UNCY 3
- Target Price
- FORA $5.00
- UNCY $5.33
- AVG Volume (30 Days)
- FORA 8.9K
- UNCY 787.6K
- Earning Date
- FORA 03-27-2025
- UNCY 05-12-2025
- Dividend Yield
- FORA N/A
- UNCY N/A
- EPS Growth
- FORA N/A
- UNCY N/A
- EPS
- FORA N/A
- UNCY N/A
- Revenue
- FORA $19,709,723.00
- UNCY N/A
- Revenue This Year
- FORA N/A
- UNCY N/A
- Revenue Next Year
- FORA $13.59
- UNCY N/A
- P/E Ratio
- FORA N/A
- UNCY N/A
- Revenue Growth
- FORA N/A
- UNCY N/A
- 52 Week Low
- FORA $1.96
- UNCY $0.20
- 52 Week High
- FORA $4.03
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- FORA 42.64
- UNCY 44.85
- Support Level
- FORA $2.05
- UNCY $0.60
- Resistance Level
- FORA $2.13
- UNCY $0.65
- Average True Range (ATR)
- FORA 0.10
- UNCY 0.05
- MACD
- FORA 0.00
- UNCY -0.00
- Stochastic Oscillator
- FORA 0.00
- UNCY 11.20
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.